What's the current outlook for Arzerra these days? I was taking an initial look at Genmab and doing a bit of DD on the company. Only a ~$350M market cap (looks like it was once $3B in the mid-2000s) with about $200M in cash and seems like they have a nice antibody pipeline led by Arzerra and complemented with solid partners in GSK, Roche, and SGEN. Looks like Arzerra 1Q12 sales grew 32% over 1Q11 sales to about $20M. Are the original projections from the former CEO, and analysts, projecting annual Arzerra sales of over $2B still possible? Looks like the drug is only approved for CLL with Phase 3 trials ongoing in FL, RA, and DBLCL. I'm assuming they'll need approvals in all of these indications to hope to get anywhere near those initial projections. And I guess I wonder how Arzerra stacks up to the current competition, including PCYC's BTK drug.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.